NCT04485663 - A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects | Biotech Hunter

Enrollment

103

Participants

Timeline

Start Date

August 17, 2020

Primary Completion Date

March 8, 2022

Study Completion Date

March 8, 2022

Conditions

Chronic Hepatitis B

Interventions

DRUG

ALG-010133

Single or multiple doses of ALG-010133

DRUG

Placebo

Single or multiple doses of Placebo

Trial Locations (10)

The First Hospital of Jilin University, Changchun

Nanfang Hospital of Southern Medical University, Guangzhou

Queen Mary Hospital, Hong Kong

"PMSI Republican Clinical Hospital T. Mosneaga, ARENSIA Exploratory Medicine Phase I Unit", Chisinau

ACS, Auckland

Pusan National University Hospital, Busan

Asan Medical Center, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Yonsei University Health System, Seoul

King's College Hospital, London